Metallothionein (MT2A) Human shRNA Plasmid Kit (Locus ID 4502)
CAT#: TR319082
MT2A - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector, 5µg of each construct provided
Need custom shRNA service?
Get a free quote
CNY 4,790.00
货期*
现货
规格
Cited in 1 publication. |
Product images
![](https://cdn.origene.com/img/defaults-img.jpg)
经常一起买 (2)
Specifications
Product Data | |
Product Name | Metallothionein (MT2A) Human shRNA Plasmid Kit (Locus ID 4502) |
Locus ID | 4502 |
UniProt ID | P02795 |
Synonyms | MT-2; MT-II; MT2 |
Vector | pRS |
Format | Retroviral plasmids |
Kit Components | MT2A - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector(Gene ID = 4502). 5µg purified plasmid DNA per construct29-mer scrambled shRNA cassette in pRS Vector, TR30012, included for free. |
RefSeq | BC007034, NM_005953, NM_005953.1, NM_005953.2, BC007034.1, BC062435, BC070289, BM746626, NM_005953.5 |
Summary | This gene is a member of the metallothionein family of genes. Proteins encoded by this gene family are low in molecular weight, are cysteine-rich, lack aromatic residues, and bind divalent heavy metal ions, altering the intracellular concentration of heavy metals in the cell. These proteins act as anti-oxidants, protect against hydroxyl free radicals, are important in homeostatic control of metal in the cell, and play a role in detoxification of heavy metals. The encoded protein interacts with the protein encoded by the homeobox containing 1 gene in some cell types, controlling intracellular zinc levels, affecting apoptotic and autophagy pathways. Some polymorphisms in this gene are associated with an increased risk of cancer. [provided by RefSeq, Sep 2017] |
shRNA Design | These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service. |
Performance Guaranteed | OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples. For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred). |
Citations (1)
The use of this RNAi has been cited in the following citations: |
---|
Development of an Integrated Genomic Classifier for a Novel Agent in Colorectal Cancer: Approach to Individualized Therapy in Early Development
,Todd M. Pitts, Aik Choon Tan, Gillian N. Kulikowski, John J. Tentler, Amy M. Brown, Sara A. Flanigan, Stephen Leong, Christopher D. Coldren, Fred R. Hirsch, Marileila Varella-Garcia, Christopher Korch, and S. Gail Eckhardt,
Clin. Cancer Res., Jun 2010; 16: 3193 - 3204
[MT2A]
|
Documents
Product Manuals |
FAQs |
SDS |
Customer
Reviews
Loading...